ENZO BIOCHEM INC (ENZ)
US2941001024 - Common Stock
Overall ENZ gets a fundamental rating of 2 out of 10. We evaluated ENZ against 109 industry peers in the Health Care Providers & Services industry. While ENZ seems to be doing ok healthwise, there are quite some concerns on its profitability. ENZ does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ENZ has reported negative net income.
ENZ had a negative operating cash flow in the past year.
In multiple years ENZ reported negative net income over the last 5 years.
ENZ had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ENZ (-30.41%) is worse than 83.33% of its industry peers.
With a Return On Equity value of -46.47%, ENZ is not doing good in the industry: 68.52% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.41% | ||
| ROE | -46.47% | ||
| ROIC | N/A |
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENZ has a better Gross Margin (45.86%) than 74.07% of its industry peers.
ENZ's Gross Margin has improved in the last couple of years.
ENZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
2. Health
2.1 Basic Checks
ENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENZ has more shares outstanding than it did 1 year ago.
ENZ has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ENZ has been reduced compared to a year ago.
2.2 Solvency
ENZ has an Altman-Z score of -3.43. This is a bad value and indicates that ENZ is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.43, ENZ is doing worse than 87.04% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that ENZ is not too dependend on debt financing.
ENZ has a better Debt to Equity ratio (0.00) than 84.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.43 |
ROIC/WACCN/A
WACC9.48%
2.3 Liquidity
ENZ has a Current Ratio of 2.82. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ENZ (2.82) is better than 87.04% of its industry peers.
ENZ has a Quick Ratio of 2.55. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
ENZ has a Quick ratio of 2.55. This is amongst the best in the industry. ENZ outperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.82 | ||
| Quick Ratio | 2.55 |
3. Growth
3.1 Past
ENZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.48%.
The Revenue for ENZ has decreased by -60.99% in the past year. This is quite bad
The Revenue for ENZ have been decreasing by -17.04% on average. This is quite bad
EPS 1Y (TTM)-33.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-160.98%
Revenue 1Y (TTM)-60.99%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-75.77%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ENZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ENZ has a Yearly Dividend Yield of 14.29%, which is a nice return.
The stock price of ENZ dropped by -40.68% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
ENZ's Dividend Yield is rather good when compared to the industry average which is at 2.98. ENZ pays more dividend than 100.00% of the companies in the same industry.
ENZ's Dividend Yield is rather good when compared to the S&P500 average which is at 2.24.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 14.29% |
5.2 History
ENZ does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ENZO BIOCHEM INC
NYSE:ENZ (12/18/2024, 10:31:03 AM)
0.7269
+0.03 (+3.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap38.28M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 14.29% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.41% | ||
| ROE | -46.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.86% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.82 | ||
| Quick Ratio | 2.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-33.48%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-60.99%
Revenue growth 3Y-35.29%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y